Tourmaline Bio Inc. (TRML) — Strategic Asset Allocation Index
Tourmaline Bio Inc. (TRML) has a Strategic Asset Allocation Index of 6.6% as of June 2025. Strategic assets (PP&E of $- plus long-term investments of $17.18 Million) total $17.18 Million, measured against net assets of $259.19 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See TRML net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Tourmaline Bio Inc. Strategic Asset Allocation Index (2023–2024)
This chart shows how Tourmaline Bio Inc.'s Strategic Asset Allocation Index has evolved across 2 annual periods from 2023 to 2024. As of June 2025, the index stands at 6.6%, representing strategic assets of $17.18 Million against net assets of $259.19 Million USD. For live market cap and overall valuation, see TRML market cap.
Annual Strategic Asset Allocation Index for Tourmaline Bio Inc. (2023–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for Tourmaline Bio Inc. from 2023 to 2024, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See shareholders equity of Tourmaline Bio Inc. for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 12.2% | $36.63 Million | $- | $36.63 Million | $300.05 Million | ▲ +12.2 pp |
| 2023 | 0.0% | $0.00 | $- | $0.00 | $205.04 Million | — |